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Summary Invasive anal cancers are generally successfully treated by combined chemother-
apy with radiation therapy (XRT). For those patients who locally fail this intervention many are
salvaged by surgery which generally results in permanent colostomy. We examined the treat-
ment and outcome of Photofrin® based photodynamic therapy (PDT) in a cohort of patients with
anal cancer who failed locally despite chemo-radiation (N = 6) and two patients with positive
margins of resection after excision of small T1 squamous cell anal cancers who refused further
surgery or chemo-radiation. PDT consisted of outpatient infusion of Photofrin® at 1.2mg/kg fol-
lowed 48 h later by outpatient illumination. Red light (630 nm) illumination was delivered by a
5 cm diffusing ﬁber, treating transphincterally at 300 J/cm followed by microlens illumination at
200 J/cm2 to the perianal tumor bed with 2 cm margin. All patients completed PDT without inci-
dent and all have maintained local control of disease in the anal region for the length of follow
up (18—48 months). PDT may serve as a new means to salvage local failures and perhaps could
be employed as a primary treatment modality in select patients with early stage of disease.
© 2010 Elsevier B.V. All rights reserved.
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Introduction
Anal cancer treatment for invasive squamous cell carcinoma
has undergone a paradigm shift away from surgery to chemo-
radiation [1]. This has allowed for sphincter sparing therapy
with equivalent outcomes to the classical approach of radi-
cal surgery with resultant permanent colostomy [2].
1572-1000/$ — see front matter © 2010 Elsevier B.V. All rights reserved.
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Table 1 Patient characteristics and outcomes.
Patient Age Male/female Stage Initial Tx Status
1 41 Male T1 (1 cm) Wide Excision NED — 48 months
2 36 Female T1 (1 cm) Wide Excision NED — 36 months
3 45 Male T2 Chemo-XRT NED — 24 months
4 70 Female T3 Chemo-XRT NED — 48 months
5 51 Female T3 Chemo-XRT NED — 48 months
6 48 Male T3 Chemo-XRT NED — 18 months
7 57 Female T3 Chemo-XRT Systemic failure
8 60 Female T3 Chemo-XRT Systemic failure
Due to the high risk of pelvic and inguinal nodal metas-
tasis, all but the earliest stage anal cancers undergo
comprehensive nodal radiation with resultant excellent con-
trol of these regions [3]. However, many patients with bulky
primary anal tumors fail locally and undergo salvage exon-
erative types of surgery with loss of a still functioning
sphincter [4]. In select patients perhaps further salvage
therapy directed to the recurrent anal tumor bed may be
possible. However, this option is rarely pursued due to the
inherent damage to normal surrounding tissues caused by
chemo-radiation with its resultant high risk of wound heal-
ing issues. Further, patients with in situ and very early stage
disease where the probability of lymphatic metastasis is very
low may undergo very aggressive regional treatment need-
lessly. In these cases, aggressive local therapy to the anal
tumor alone may be successful.
Photodynamic therapy is a tumor ablative treatment
technique that has achieved high response rates for a myriad
of tumors, of various histology’s both deep seated and cuta-
neous in origin [5,6]. During PDT, a photosensitizing agent is
applied and then activated by the appropriate wavelength
and intensity of light to create a type II redox reaction
that creates singlet oxygen. This reactive species lead to
rapid vascular shut down as well as tissue necrosis and/or
apoptosis. What is relativity unique about PDT is that the
commercially available photosensitizer, Photofrin®, does not
appear to concentrate in connective tissue, allowing for
superior tissue healing even in heavily pretreated anatomy.
We examined the role of photodynamic therapy in a
cohort of anal cancer patients who locally failed chemo-
radiation at the primary tumor site and two individuals
who refused chemo-radiation or additional surgery for early
stage anal cancer.
Materials and methods
All patients signed informed consent. Patients with local
recurrence following chemo-radiation had biopsy proven
invasive squamous cell cancer. Restaging included chest,
abdomen, and pelvic CT scan in all cases, which at the time
of restaging were without evidence of regional or systemic
failure. Patients with T1 stage anal disease failed wide local
excision and also were similarly restaged and found not to
have evidence of regional or systemic disease. All patients
refused surgical salvage which would have consisted of per-
manent colostomy and loss of sphincter. The early stage
patients with recurrence also refused chemo-radiation as
well. Patient characteristics are noted in Table 1.
Figure 1 Home made device for PDT of anal cancer.
PDT consisted of off label outpatient infusion of
Photofrin® (Axcan Pharma) at 1.2mg/kg. After 48 h, the
patient was illuminated in an outpatient setting. Illumina-
tion was at 630 nanometers via red light generated from a
Diomed diode laser. A bowel prep 24 h prior to illumination
was done for all patients. Illumination consisted of placing
the patient in a lithotomy position with anal insertion of
a clear plastic test tube (Fig. 1). There was a 58.7% light
attenuation in the test tube which was accounted for in
the treatment. The 5 cm diffusing ﬁber catheter was placed
inside the test tube to allow for 2 cm superior and at least
2 cm inferior to the sphincter illumination (Fig. 2). A total
of 300 J/cm was then delivered. Immediately following, a
handheld microlens outlying the gross or recurrent region of
Figure 2 Home made device inserted rectally at the time of
therapy.
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Figure 3 48-h post-PDT, no normal tissue damage, sphincter
functioning well.
perianal disease was used to illuminate the target with 2 cm
margin, delivering 200 J/cm2. In all patients, one diffusing
and one microlens illumination was accomplished.
Following PDT, patients were observed for 1 h and then
discharged with follow up at 24 and 48 h post-PDT. Immedi-
ately following PDT, a Medrol dose pack was dispensed as was
1 week worth of Keﬂex antibiotics. All patients were imme-
diately placed on oral narcotic analgesia. They were also
instructed to use ice packs peri-anally and to maintain very
soft stool by softeners. When feasible additional narcotic
pain relievers were to be used prior to bowel movement.
Results
All patients underwent PDT as prescribed with none lost
to follow up. The treatment procedure was well tolerated
without undue or unexpected morbidity. All therapy was
outpatient with no emergency room or hospital admission
required from PDT. No morbidity from Photofrin® infusion
was recognized and no patient experienced sunlight photo-
sensitivity.
Immediately post-PDT, the tumor bed appeared dusky,
erethematous, and began weeping. Interestingly, no patient
reported any pain at this point. At 24 h follow up the tumor
bed remained dusky but no longer was with ﬂuid loss. Normal
tissue appeared clinically unchanged from non-illuminated
regions. The treatment sites were very tender to palpation.
Similar ﬁndings were noted at 48 h (Fig. 3). All patients were
in control of their sphincters for gas and bowel movement
during this time.
About 6—12 h post-PDT patients experienced an increase
in pain in the anal region, most notable on bowel movement
and prolonged sitting. By employing additional narcotics for
this break-through pain they were able to minimize these
discomforts. The intensity of this discomfort diminished dra-
matically by 72—96 h in all cases. The addition of an ice pack
applied to the anal region offered excellent and rapid short-
term relief. Narcotic use was intermittent from the end of
the ﬁrst week forward and was not necessary at 1 month
post-PDT.
Patients were then followed at monthly or less fre-
quent periods. At the ﬁrst month follow up gross tumor was
necrotic and appeared to have healing at the periphery. No
patient had signiﬁcant pain at this point and all were back to
regular routine exams. Each patient had re-biopsy between 3
and 4 months post-PDT with all showing NED. At 6 months all
patients were re-staged. None showed local or pelvic recur-
rence but two patients had evidence of systemic disease
and were placed on chemotherapy. At last follow up (18—48
months) no patient had local failure, wound healing issues
or sphincter damage from PDT.
Discussion
While comprising only 1% of gastro intestinal malignan-
cies, invasive squamous cell anal cancers are unique in that
chemo-radiation alone can be curative in a substantial num-
ber of individuals with this diagnosis [7]. This ﬁnding came
about when several anal cancer patients had pathologic
complete response on a pre-op chemo-radiation protocol
pioneered by Nigro [8]. Subsequent studies conﬁrmed the
efﬁcacy of chemo-radiation on squamous lesions of the anal
canal region so this approach has become standard of care
for several decades.
With further evaluation it has become evident that
patients with bulky tumors (T3) treated with chemo-
radiation have a local failure rate approaching 10—20% or
more [9]. Most of these patients will then undergo radi-
cal surgery for salvage with resultant permanent colostomy.
While this salvage approach ultimately offers high rates
of local control it is a morbid procedure with permanent
change in lifestyle. In addition, it has also been described
that patients with in situ or early T1 squamous cell lesions
may do well with only local treatment to the primary site
generally with a sphincter sparing surgical approach [10].
While not necessarily standard of care this treatment avoids
the high acute and chronic morbidity associated with chemo-
radiation protocols. A small literature exists that shows local
surgery may offer a signiﬁcant control rate without evidence
of pelvic or inguinal failure in very select patients with early
stage anal cancer.
As most local failures for anal cancer have undergone
radical chemo-radiation, the normal tissue tolerance of the
sphincter region has been approached [11]. Therefore, fur-
ther radiation as a means of salvage would be highly morbid
and result in functional sphincter loss. As these tissues heal
poorly after chemo-radiation, a local sphincter sparing sur-
gical approach to salvage is also generally contraindicated.
As such most patients end up with permanent colostomy.
PDT has an excellent track record of tumor ablation with
the potential for normal tissue maintenance [12]. This is
attributed to the relative lack of photosensitizer accumu-
lation in connective tissue. When tumor is ablated by PDT
the normal tissue infrastructure is maintained allowing for
wound healing even in heavily irradiated tissue. Therefore,
PDT may be an ideal therapy for local salvage of anal cancer
failures. Further, if ablation without sphincter loss were pos-
sible then this might also be an ideal option for patients with
local failure following surgery alone for early invasive/in situ
disease.
A pair of publications reported the potential sphinc-
ter sparing and excellent cosmetic outcome possible for
a small group of ﬁve patients who failed local exci-
sion of in situ squamous cell or Paget’s disease of the
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peri-anal region [13,14]. All patients failed wide local exci-
sion and more radical surgery was planned, which may
have required colostomy. Instead all patients were infused
with 1mg/kg of Photofrin® and surface illumination at
200—250 J/cm2 followed at 24—48 h post-infusion. In this
series, patients were treated as inpatients, but the authors
concluded that outpatient therapy would have been possi-
ble for all. Pain control was needed for 72—96 h post-PDT.
Immediate erythema and blister formation was noted in
all patients with excellent tissue healing by 2 months.
All maintained functioning sphincters. Biopsy proven
local control was maintained for several years in three
patients.
Subsequently, several case reports on PDT of peri-anal
in situ lesions have been published. Hamdan et al. [15]
employed topical ALA in two sessions, achieving complete
response for intraepithelial neoplasia. Similarly, perianal
Paget’s disease was treated with success by Li et al. [16].
In an interesting case report Li et al. [17] employed ALA to
ﬁrst ﬂuoresce and then treat an extensive perianal Paget’s
lesion, In this protocol, topical ALA was placed on the lesion
for 3 h and ﬂuorescence was then used to guide the illumi-
nation ﬁeld size for therapy. A second course of ALA and
Hiporﬁn PDT followed 40 days later with the patient achiev-
ing complete response. Webber and Fromm [18] employed
PDT in HIV positive patients for carcinoma in situ of the anus.
These ﬁve patients were given ALA orally. About 4 h later
the entire anal circumference was illuminated. Local control
was excellent but all patients developed temporary abnor-
malities on subsequent liver function testing, attributed to
oral ALA. Van der Snoek et al. [19] reported on the use of
topical Foscan® (FOSGEL) for high grade anal intraepithelial
neoplasia. In this series of nine HIV positive patients, topical
FOSGEL was applied and illuminated 8 h later at 652 nm with
20 J/cm2. A second treatment followed at 7 days. No clinical
or histological response was seen and the authors concluded
the therapy ineffective.
A small body of PDT literature also shows the potential
for PDT salvage of local failures in rectal cancers. PDT alone
or as an adjunct to surgery for local recurrence was possi-
ble with Photofrin® PDT in an early report by Harlow et al.
[20]. Similarly, PDT or other local ablative techniques may
be employed for extended palliation by endoscopic based
therapy as was outlined by Dohmoto et al. [21]. A review of
outcome, showing the potential role of PDT for this indica-
tion was recently published by Wang and Liu [22]. The author
found excellent control of signs and symptoms of local recur-
rence with various PDT treatment regimens, however these
ﬁndings are based on very small series of patients.
The patients in our series were generally chemo-radiation
failures at the primary tumor site. The next step for this
group was a surgical procedure with permanent colostomy
due to the invasive nature of the recurrence. On re-staging
none of these patients appeared to have evidence of pelvic
or distant failure and as such a sphincter sparing attempt by
PDT appeared reasonable. Two patients had early lesions
with involved resection margins. Potentially further local
excision would have been an option but the location of the
re-excision would likely compromise sphincter function. As
such PDT was offered since both of these patients refused
chemo-radiation. Staging did not reveal any evidence of
adenopathy at the time of PDT.
In all cases PDT was delivered by a combination of dif-
fuser and microlens. A clear plastic test tube was slid into
the sphincter, closed side ﬁrst. A diffuser was then slid
inside so that about 2 cm of the light diffuser was above
the sphincter and 2 cm or more was below. This allowed for
easy trans-sphincter illumination. In addition, a microlens
was then employed to the local tumor bed and peri-anal
skin region at risk with at least 2 cm margins. We employed
300 J/cm via the diffuser and 200 J/cm2 by the microlens.
All patients had clinical response in the treatment region
by illuminations end. The tumor or tumor bed was gener-
ally dusky and weeping. Normal surrounding tissue did not
develop the weeping phenomena. We did not see signiﬁ-
cant tissue slough from tumor or normal tissue. Rather at
24—48 h post-PDT the tumor bed remained darkened and
hypoxic appearing with surrounding normal tissue appeared
undifferentiated from untreated areas. All patients main-
tained normal sphincter function for stool and gas from the
immediate treatment period through follow up. The actual
PDT session was pain free and easily accomplished as an
out patient procedure. However, after 6—12 h all patients
experienced moderate peri-anal discomfort so that sitting
or bowel movement was of clinical signiﬁcance. This was
made tolerable by narcotic analgesia, which was required
round the clock for about 72 h with additional pain medica-
tion dispensed prior to bowel movement. Pain medication
was required intermittently for at least 4 weeks post-PDT.
Patients were placed on stool softeners which made recov-
ery easier. No photosensitivity was reported or seen on
clinical exam.
Using this treatment technique and a drug dose of
1.2mg/kg with illumination at 48 h post-infusion, biopsy
proven local control was maintained in all 8 patients.
Minimum follow up was 18 months. All patients main-
tained sphincter function throughout follow up. Of note two
patients developed systemic disease, but none developed
pelvic or inguinal failure. Both patients with early invasive
cancer have remained NED.
Conclusion
Photofrin® Photodynamic therapy appears to be an effective
local treatment for recurrent and/or persistent squamous
cell cancers of the anal canal. At the drug dose and light
dose employed lesion ablation is possible as is retention of
a functioning sphincter. Given the good outcomes presented
we believe that PDT may be an option for sphincter sparing
salvage therapy and perhaps an up front treatment for early
stage disease. This should be evaluated in a larger clinical
trial.
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